Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (linagliptin)
Drug: Placebo (sitagliptin)
Drug: Sitagliptin
Drug: Linagliptin

First Posted Date: 2008-07-16

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 121

Registration Number: NCT00716092

Locations: 🇩🇪
1218.37.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
1218.37.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪
1218.37.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2008-07-15

Last Posted Date: 2014-12-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT00715403

Locations: 🇩🇪
1199.16.49004 Boehringer Ingelheim Investigational Site, Grosshansdorf, Germany
🇫🇷
1199.16.3306A Boehringer Ingelheim Investigational Site, Bordeaux cedex, France
🇫🇷
1199.16.3311B Boehringer Ingelheim Investigational Site, Clichy Cedex, France

and more 8 locations

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BIBW 2992 MA2 40mg/day
Drug: BIBW 2992 QD
Drug: BIBW 2992 MA2 50mg/day
Drug: BIBW 2992 MA2 20mg/day

First Posted Date: 2008-07-09

Last Posted Date: 2015-01-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT00711594

Locations: 🇯🇵
1200.33.006 Boehringer Ingelheim Investigational Site, Miyakojima-ku, Osaka, Japan
🇯🇵
1200.33.010 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan
🇯🇵
1200.33.003 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba, Japan

and more 17 locations

A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasms

Interventions: Drug: BIBF1120
Drug: Placebo

First Posted Date: 2008-07-04

Last Posted Date: 2016-08-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 89

Registration Number: NCT00710762

Locations: 🇬🇧
1199.9.4405 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧
1199.9.4410 St James's University Hospital, Leeds, United Kingdom
🇬🇧
1199.9.4402 Boehringer Ingelheim Investigational Site, Northwood, United Kingdom

and more 8 locations

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: BI 2536

First Posted Date: 2008-07-04

Last Posted Date: 2022-05-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 89

Registration Number: NCT00710710

Locations: 🇩🇪
1216.10.49013 Boehringer Ingelheim Investigational Site, Celle, Germany
🇩🇪
1216.10.49007 Boehringer Ingelheim Investigational Site, Essen, Germany
🇦🇹
1216.10.43001 Boehringer Ingelheim Investigational Site, Wien, Austria

and more 7 locations

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: BIBW 2992
Drug: Letrozole

First Posted Date: 2008-07-02

Last Posted Date: 2013-12-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT00708214

Locations: 🇫🇷
1200.5.3306A Boehringer Ingelheim Investigational Site, Caen Cedex, France
🇫🇷
1200.5.3304A Boehringer Ingelheim Investigational Site, Nice Cedex 2, France
🇫🇷
1200.5.3302A Boehringer Ingelheim Investigational Site, Saint Cloud, France

and more 2 locations

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2008-06-27

Last Posted Date: 2015-01-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 87

Registration Number: NCT00706628

Locations: 🇬🇧
1239.3.4402 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom
🇬🇧
1239.3.4406 Boehringer Ingelheim Investigational Site, Bournemouth, United Kingdom
🇬🇧
1239.3.4408 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom

and more 6 locations

Phase II Study of BI 2536 in Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2008-06-27

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT00706498

Locations: 🇬🇧
1216.19.4405 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom
🇬🇧
1216.19.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧
1216.19.4407 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom

and more 3 locations

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

First Posted Date: 2008-06-19

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 71

Registration Number: NCT00701766

Locations: 🇩🇪
1216.20.49007 Boehringer Ingelheim Investigational Site, Heidelberg, Germany
🇦🇹
1216.20.43002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇩🇪
1216.20.49002 Boehringer Ingelheim Investigational Site, Frankfurt, Germany

and more 6 locations

BI 811283 in Various Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 811283

First Posted Date: 2008-06-19

Last Posted Date: 2014-07-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 124

Registration Number: NCT00701324

Locations: 🇩🇪
1247.1.49001 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany
🇩🇪
1247.1.49002 Boehringer Ingelheim Investigational Site, Essen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy